232 related articles for article (PubMed ID: 3013134)
1. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of herpes simplex virus glycoprotein gB-1-related protein produced in yeast.
Kino Y; Nozaki C; Nakatake H; Mizuno K; Mori R
Vaccine; 1989 Apr; 7(2):155-60. PubMed ID: 2546329
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
5. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.
Dix RD; Mills J
J Med Virol; 1985 Sep; 17(1):9-18. PubMed ID: 2995573
[TBL] [Abstract][Full Text] [Related]
6. Yeast-derived glycoprotein B-1 of herpes simplex virus (HSV) as a candidate for an HSV vaccine.
Kino Y
Adv Exp Med Biol; 1990; 278():183-90. PubMed ID: 1963033
[No Abstract] [Full Text] [Related]
7. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
[TBL] [Abstract][Full Text] [Related]
8. Comparative studies of HSV-1 antigens solubilised from infected cells by using non-ionic or zwitterionic detergents.
Jennings R; Erturk M
J Med Virol; 1990 Jun; 31(2):98-108. PubMed ID: 2167352
[TBL] [Abstract][Full Text] [Related]
9. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B
Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288
[TBL] [Abstract][Full Text] [Related]
10. Passive immunization of mice with monoclonal antibodies to glycoprotein gB of herpes simplex virus.
Kino Y; Eto T; Ohtomo N; Hayashi Y; Yamamoto M; Mori R
Microbiol Immunol; 1985; 29(2):143-9. PubMed ID: 2989659
[TBL] [Abstract][Full Text] [Related]
11. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
13. An adenovirus-herpes simplex virus glycoprotein B recombinant (Ad-HSV.gB) protects mice against a vaccinia HSV.gB and HSV challenge.
Endresz V; Berencsi K; Gönczöl E
Acta Microbiol Immunol Hung; 1995; 42(3):247-54. PubMed ID: 8548197
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs.
Bernstein DI; Miller RL; Harrison CJ
J Infect Dis; 1993 Mar; 167(3):731-5. PubMed ID: 8382722
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein gB of herpes simplex virus expresses type-common and type-specific antigenic determinants in vivo.
Dix RD
J Med Virol; 1990 Mar; 30(3):192-5. PubMed ID: 1692872
[TBL] [Abstract][Full Text] [Related]
16. Mice genetic immunization with plasmid DNA encoding a secreted form of HSV-1 gB induces a protective immune response against herpes simplex virus type 1 infection.
Caselli E; Grandi P; Argnani R; Balboni PG; Selvatici R; Manservigi R
Intervirology; 2001; 44(1):1-7. PubMed ID: 11223713
[TBL] [Abstract][Full Text] [Related]
17. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
Roberts PL; Duncan BE; Raybould TJ; Watson DH
J Gen Virol; 1985 May; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
[TBL] [Abstract][Full Text] [Related]
18. Native HSV glycoprotein D subunit vaccine: analysis of in vitro T-cell activation and antigen presentation.
Ishizaka ST; Mishkin EM
Viral Immunol; 1991; 4(3):187-93. PubMed ID: 1667262
[TBL] [Abstract][Full Text] [Related]
19. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
[TBL] [Abstract][Full Text] [Related]
20. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D.
Geerligs HJ; Weijer WJ; Welling GW; Welling-Wester S
J Immunol Methods; 1989 Nov; 124(1):95-102. PubMed ID: 2553820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
